Fresenius Medical Care Analyst Ratings
Fresenius Medical Care Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 39.49% | Truist Securities | $28 → $24 | Maintains | Hold |
| 07/13/2023 | 62.74% | Truist Securities | $26 → $28 | Maintains | Hold |
| 05/10/2023 | 51.12% | Truist Securities | $24 → $26 | Maintains | Hold |
| 04/13/2023 | 39.49% | Truist Securities | $22 → $24 | Maintains | Hold |
| 02/23/2023 | 27.87% | Truist Securities | $17 → $22 | Maintains | Hold |
| 06/22/2022 | 56.93% | Truist Securities | $34 → $27 | Maintains | Hold |
| 11/23/2021 | — | HSBC | Initiates Coverage On | → Hold | |
| 11/17/2021 | 103.43% | RBC Capital | $42 → $35 | Maintains | Sector Perform |
| 11/11/2021 | — | Jefferies | Upgrades | Underperform → Hold | |
| 05/21/2020 | 178.99% | SunTrust Robinson Humphrey | $46 → $48 | Maintains | Buy |
| 05/11/2020 | 167.36% | SunTrust Robinson Humphrey | $42 → $46 | Maintains | Buy |
| 04/13/2020 | 144.12% | SunTrust Robinson Humphrey | $46 → $42 | Maintains | Buy |
| 02/21/2020 | 167.36% | CFRA | $38 → $46 | Upgrades | Hold → Buy |
| 01/21/2020 | — | Jefferies | Upgrades | Hold → Buy | |
| 10/23/2019 | — | Redburn Partners | Downgrades | Buy → Neutral | |
| 08/01/2019 | — | BTIG | Downgrades | Buy → Neutral | |
| 06/20/2019 | — | Barclays | Upgrades | Equal-Weight → Overweight | |
| 10/26/2018 | — | UBS | Upgrades | Neutral → Buy | |
| 10/18/2018 | — | DZ Bank | Downgrades | Buy → Hold |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月11日 | 39.49% | Truist证券 | $28→$24 | 维护 | 保持 |
| 07/13/2023 | 62.74% | Truist证券 | $26→$28 | 维护 | 保持 |
| 2023年05月10日 | 51.12% | Truist证券 | $24→$26 | 维护 | 保持 |
| 04/13/2023 | 39.49% | Truist证券 | $22→$24 | 维护 | 保持 |
| 02/23/2023 | 27.87% | Truist证券 | $17→$22 | 维护 | 保持 |
| 2022/06/22 | 56.93% | Truist证券 | $34→$27 | 维护 | 保持 |
| 2021年11月23日 | - | 汇丰银行 | 开始承保 | →保留 | |
| 2021年11月17日 | 103.43% | 加拿大皇家银行资本 | $42→$35 | 维护 | 行业表现 |
| 2021年11月11日 | - | 杰富瑞 | 升级 | 表现不佳的→保持 | |
| 2020/05/21 | 178.99% | SunTrust Robinson Humphrey | $46→$48 | 维护 | 买 |
| 05/11/2020 | 167.36% | SunTrust Robinson Humphrey | $42→$46 | 维护 | 买 |
| 04/13/2020 | 144.12% | SunTrust Robinson Humphrey | $46→$42 | 维护 | 买 |
| 02/21/2020 | 167.36% | CFRA | $38→$46 | 升级 | 持有→购买 |
| 2020/01/21 | - | 杰富瑞 | 升级 | 持有→购买 | |
| 2019年10月23日 | - | Redburn合作伙伴 | 评级下调 | 购买→中性 | |
| 2019年08月01日 | - | BTIG | 评级下调 | 购买→中性 | |
| 2019年06月20日 | - | 巴克莱 | 升级 | 等重→超重 | |
| 2018年10月26日 | - | 瑞银集团 | 升级 | 中性→购买 | |
| 2018年10月18日 | - | 德国中央合作银行 | 评级下调 | 购买→Hold |
What is the target price for Fresenius Medical Care (FMS)?
费森尤斯医疗保健(FMS)的目标价格是多少？
The latest price target for Fresenius Medical Care (NYSE: FMS) was reported by Truist Securities on October 11, 2023. The analyst firm set a price target for $24.00 expecting FMS to rise to within 12 months (a possible 39.49% upside). 5 analyst firms have reported ratings in the last year.
TRUIST证券于2023年10月11日报道了费森尤斯医疗保健公司(纽约证券交易所代码：FMS)的最新目标价。这家分析公司将目标价定为24美元，预计FMS将在12个月内上涨至39.49%。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Fresenius Medical Care (FMS)?
费森尤斯医疗保健(FMS)的最新分析师评级是多少？
The latest analyst rating for Fresenius Medical Care (NYSE: FMS) was provided by Truist Securities, and Fresenius Medical Care maintained their hold rating.
费森尤斯医疗保健公司(纽约证券交易所代码：FMS)的最新分析师评级由Truist Securities提供，费森尤斯医疗保健公司维持其持有评级。
When is the next analyst rating going to be posted or updated for Fresenius Medical Care (FMS)?
费森尤斯医疗保健(FMS)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fresenius Medical Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fresenius Medical Care was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与费森尤斯医疗保健公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。费森尤斯医疗保健的上一次评级是在2023年10月11日提交的，因此您应该预计下一次评级将在2024年10月11日左右提供。
Is the Analyst Rating Fresenius Medical Care (FMS) correct?
分析师对费森尤斯医疗保健(FMS)的评级正确吗？
While ratings are subjective and will change, the latest Fresenius Medical Care (FMS) rating was a maintained with a price target of $28.00 to $24.00. The current price Fresenius Medical Care (FMS) is trading at is $17.20, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的费森尤斯医疗保健(FMS)评级保持不变，目标价在28.00美元至24.00美元之间。费森尤斯医疗保健(FMS)目前的交易价格为17.20美元，超出了分析师的预测范围。